The $1,000 Cancer Test That Isn’t Saving Lives
The headlines sounded incredible…
A simple blood test that can detect more than 50 different cancers before symptoms appear.
No invasive procedures. No scans. No biopsies.
Just one tube of blood.
These so-called “multicancer early detection (MCED) tests” were being called the future of cancer screening.
All for the low, low price of $1,000 a pop.
The only problem?
These tests just failed the very study designed to prove they actually help people.
So why are some doctors still pushing them?
We’ll tell you everything you need to know – including how to keep your health and your wallet safe.
The premise seems pretty simple…
MCED tests search your bloodstream for tiny fragments of DNA that may have come from cancer cells.
Find cancer earlier. Treat it sooner. Save more lives.
Who wouldn’t want that?
To find out if it actually works, researchers enrolled nearly 143,000 people in the largest trial of its kind.
The goal was straightforward: determine whether adding the blood test to standard cancer screening would reduce the number of dangerous late-stage cancers being diagnosed.
And…it didn’t.
The trial failed its primary goal, even though the research was funded by the very company that makes the test.
The people getting the blood test weren’t any less likely to end up with advanced stage III and stage IV cancers.
So much for early detection and treatment, right?
But, trust me, the problems with these MCED tests don’t end there.
The fact is, finding more cancer is not the same thing as saving more lives.
In fact, medicine has learned this lesson the hard way before.
Researchers reported a 16% increase in stage I and II cancers being detected among those taking the test. Supporters called that encouraging.
But critics immediately asked some different questions: Are we simply finding more harmless cancers that never would have caused problems?
And are we putting people through grueling cancer treatments they may not need?
Meanwhile, many of the aggressive cancers that actually kill people may still be slipping through the cracks.
Even more concerning, a negative MCED test result doesn’t mean you’re cancer-free.
Recent reports suggest the test misses a substantial number of cancers, meaning someone could receive reassuring results while a dangerous cancer continues growing undetected.
Until this test can successfully meets its goal, marketing claims that this blood test will revolutionize cancer screening remain exactly that— marketing claims.
The goal isn’t just to find more cancer. The goal is to prevent suffering and save lives. And so far, this $1,000 blood test has not proven it can do either.
And all of the fancy marketing claims can’t change that.
To asking the tough questions,
Ray Thatcher
Research Director, Health Sciences Institute
Sources:
Kuznar, W. (2026, May 30). Multicancer early detection test fails to reduce cancers detected at late stages: However, an increase in the detection of stage I/II cancers was observed. MedPage Today. https://www.medpagetoday.com/meetingcoverage/asco/121498
